Life Sciences Investment Thesis

• Structure prediction, generative design, and cheap sequencing moved discovery cost down enough that small teams can generate credible candidates.
• Lab automation and cloud-based execution let a small company run experimental cycles that used to need a full facility.
• Regulators have working frameworks for software as a medical device and for AI-enabled tools, so approval is a process rather than an open question.
• Pharma partners are actively buying platforms and de-risked assets rather than building every capability internally.

• Discovery platforms & tools

  Protein and small molecule design, functional genomics, high-throughput assay systems, and instrumentation that generates proprietary data.

• Therapeutics

  Asset-centric programs with a defined indication, mechanism, and a translational plan through IND-enabling work.

• Diagnostics & measurement

  Molecular and imaging diagnostics, point-of-care devices, and biomarkers with a defined clinical use and reimbursement thesis.

• Bioprocessing & manufacturing

  Cell-free systems, continuous manufacturing, analytics, and cost-of-goods reduction for biologics and cell therapies.

• Clinical & regulatory software

  Trial operations, evidence generation, quality systems, and tooling that shortens the path from data to submission.

• Health infrastructure & data

  Interoperability, privacy-preserving data infrastructure, and datasets assembled with consent and provenance intact.

• Experimental validation, in the wet lab, of whatever the computational method claims.
• A regulatory path the team can describe by pathway, predicate, and expected evidence — not by aspiration.
• A reimbursement or partnering thesis for diagnostics and tools, named payer or partner included.
• Founders combining domain depth with engineering rigor, and scientific advisors who are actually engaged.
• Proprietary data that compounds because of how the company operates, not because it was purchased once.

• Models validated only against public benchmarks with no experimental follow-through.
• Diagnostics with strong performance data and no coverage or purchasing path.
• Therapeutics programs with no translational plan or with an indication chosen for trial cost alone.
• Data assets whose consent and provenance would not survive a partner's diligence.

What we underwrite against at each stage.

• Pre-seed

  Wet-lab validation of the core claim, a regulatory pathway identified, and an academic or industry collaboration in place.

• Seed

  A lead program or product with reproducible data, a paid pilot or partnership, and a costed development plan.

• Post-seed

  IND-enabling progress, clearance underway, or platform revenue from multiple partners.

What life sciences companies does HypergrowthLabs invest in?

Discovery platforms and tools, therapeutics with a defined indication, diagnostics with a reimbursement path, bioprocessing and manufacturing, clinical and regulatory software, and health data infrastructure.

Does HypergrowthLabs invest in AI-for-biology companies?

Yes, when the computational claim has been validated in the wet lab. Benchmark performance without experimental follow-through is not enough on its own.

How does HypergrowthLabs think about regulatory risk in life sciences?

We expect a team to name the pathway, the predicate or comparator where relevant, and the evidence a regulator will ask for, then plan the capital and timeline around that rather than around the science alone.